PubRank

P Tagliaferri

Author PubWeight™ 51.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003 2.26
2 Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999 1.98
3 miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012 1.40
4 A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011 1.38
5 Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003 1.21
6 Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 1999 1.13
7 Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009 1.10
8 The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem 2003 1.09
9 Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 2005 1.03
10 Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000 1.02
11 A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 2007 1.01
12 C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 2007 1.01
13 Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001 0.97
14 Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 2011 0.97
15 Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012 0.97
16 Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth. FEBS Lett 1987 0.94
17 Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer 2000 0.94
18 Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000 0.93
19 Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem J 1997 0.93
20 Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation. Cancer Invest 1989 0.91
21 Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. Blood 1988 0.90
22 EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 2003 0.89
23 Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem 2000 0.89
24 alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 1995 0.89
25 Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009 0.87
26 Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol 1998 0.86
27 Ouabain sensitivity is linked to ras -transformation in human HOS cells. Biochem Biophys Res Commun 1986 0.86
28 Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res 1991 0.86
29 Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb. Cancer Immunol Immunother 1993 0.84
30 Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets 2009 0.83
31 Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells. Anticancer Drugs 1995 0.83
32 Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. Proc Natl Acad Sci U S A 1989 0.83
33 Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy. Adv Exp Med Biol 1999 0.82
34 Pegylated liposomal doxorubicin is active in Stewart-Treves syndrome. Ann Oncol 2007 0.82
35 5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann Oncol 1994 0.82
36 Ornithine decarboxylase and diamine oxidase in human colon carcinoma cell line CaCo-2 in culture. Gastroenterology 1989 0.82
37 Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 2006 0.81
38 Tissue transglutaminase expression affects hypusine metabolism in BALB/c 3T3 cells. FEBS Lett 1998 0.81
39 Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991 0.81
40 Site-selective cAMP analogs induce nuclear translocation of the RII cAMP receptor protein in Ha-MuSV-transformed NIH/3T3 cells. FEBS Lett 1987 0.81
41 Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death Differ 2000 0.81
42 Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 1991 0.80
43 Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death. Eur J Cancer 2002 0.80
44 A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 2006 0.79
45 Extracellular adenosine 5' triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. Immunol Lett 1997 0.79
46 High-dose recombinant interleukin-2/verapamil combination in advanced cancer. Eur J Cancer 1996 0.78
47 Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP. FEBS Lett 1999 0.77
48 Methicillin-resistant Staphylococcus aureus in community-acquired meningitis. Eur J Clin Microbiol Infect Dis 2006 0.77
49 Phorbol 12-myristate 13-acetate (pma) induces neuroendocrine-like differentiation and reverses Doxorubicin-resistance of human colon-carcinoma cells in-vitro. Int J Oncol 1994 0.77
50 Levels and variability of purine nucleotides in normal human lymphocytes. Biomed Pharmacother 1992 0.77
51 Polyamine uptake by human colon carcinoma cell line CaCo-2. Digestion 1990 0.77
52 90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. Oncol Rep 1994 0.76
53 Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 2012 0.76
54 Two classes of cAMP analogs synergistically inhibit p21 ras protein synthesis and phenotypic transformation of NIH/3T3 cells transfected with Ha-MuSV DNA. Biochem Biophys Res Commun 1985 0.76
55 Cytosine arabinoside (Ara-C) plus alpha-interferon (alpha IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens. Br J Haematol 1994 0.75
56 Transmembrane ion flux modifiers verapamil and ouabain modulate cytotoxic effects of extracellular ATP on human tumor-cells in-vitro. Int J Oncol 1993 0.75
57 8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor. Br J Cancer 1999 0.75
58 Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin Cancer Res 1995 0.75
59 alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. Int J Oncol 1996 0.75
60 Maintenance therapy with recombinant interferon alpha-2B (alpha IFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL). Oncol Rep 1996 0.75
61 Tailored therapy for aggressive non-Hodgkin's lymphoma: results of a phase II study with a long-term follow-up. Int J Oncol 1998 0.75
62 Changing presentation in non-Hodgkin lymphoma. Lancet 1990 0.75
63 Alpha-interferon induces depletion of intracellular iron content and upregulation of functional transferrin receptors on human epidermoid cancer KB cells. Biochem Biophys Res Commun 1994 0.75
64 Mitoxantrone, Etoposide and bleomycin (meb) chemotherapy in non-hodgkins-lymphoma patients non-elegible for standard cyclophosphamide, Doxorubicin, vincristine and prednisone (chop) combination. Oncol Rep 1995 0.75
65 Chlorambucil, vincristine and cytarabine (COA) treatment of low grade lymphomas. Leuk Lymphoma 1995 0.75
66 Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cells. Anticancer Res 1997 0.75
67 CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia. Year Immunol 1993 0.75